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This is the first report demonstrating the in vitro inhibitory activity of two novel microbicides (cellulose
sulfate and polystyrene sulfonate) against bacterial vaginosis (BV)-associated bacteria. Vaginal application of
these microbicides not only may reduce the risk of acquisition of human immunodeficiency virus and other
sexually transmitted infection-causing organisms but may also decrease the incidence of BV.
AIDS and other sexually transmitted infections (STIs) con-
tinue to be major health threats. An attractive approach for
women to prevent the acquisition of these diseases through
vaginal intercourse is the use of antimicrobial products (mi-
crobicides) (12, 24). Nonoxynol-9, a highly cytotoxic surfactant
and detergent commonly used as an active ingredient in mar-
keted spermicidal and contraceptive formulations, possesses
broad-spectrum in vitro activity against the human immuno-
deficiency virus (HIV) and many other STI-causing organisms.
Unfortunately, nonoxonyl-9-containing products also inacti-
vate lactobacilli and can increase the occurrence of bacterial
vaginosis (BV) (16, 17). In addition, vaginal ulcerations can
result from frequent use of this compound (25). These adverse
effects are given as reasons for the unacceptability of nonoxy-
nol-9-containing spermicidal products for vaginal use to pre-
vent HIV transmission (20), and these products may even
enhance transmission (21). Alternate vaginal topical agents
need to be identified.
Two new, noncytotoxic microbicides that have reached clin-
ical trial include polystyrene sulfonate (T-PSS) and cellulose
sulfate (Ushercell). Ushercell is a long-chain sulfated polysac-
charide (1,900 kDa) and T-PSS is a long-chain sulfonated
polymer (751 kDa). Both have broad-spectrum antimicrobial
activity. They are known to inhibit HIV, human papillomavi-
rus, herpes simplex virus type 1 (HSV-1), HSV-2, Chlamydia
trachomatis, and Neisseria gonorrhoeae in vitro (1, 2, 7, 9, 26).
These compounds do not inhibit Lactobacillus gasseri in vitro at
concentrations of 5 to 50 mg/ml and have been proven to be
safe in a variety of animal studies (1, 2, 26; L. J. D. Zaneveld,
D. P. Waller, R. A. Anderson, C. Chany, and S. Garg, Program
Abstr. Microbicides 2000 Conf., p. 30, 2000). As a result, the
U.S. Food and Drug Administration approved an Investiga-
tional New Drug application for both products.
Since vaginal microbicides may be used frequently, it is im-
portant that these products minimally alter the endogenous
vaginal microflora. A concern is that these polymers may en-
hance the growth of Gardnerella vaginalis and BV-associated
anaerobes, possibly resulting in an increased incidence of BV.
BV is defined as a clinical syndrome in which the normal,
predominantly lactobacilli-containing vaginal flora are re-
placed by high concentrations of G. vaginalis, anaerobic bac-
teria, and genital mycoplasmas (11, 19). G. vaginalis appears to
play a key role in creating an environment conducive to the
development of BV (S. Faro, Editorial, Infect. Dis. Obstet.
Gynecol. 8:75). BV is one of the most common vaginal disor-
ders among reproductive-age women. It is associated with gy-
necological and obstetric complications, as well as with an
increased risk of acquisition and transmission of HIV (6, 8, 13,
18, 22).
The purpose of this study was to evaluate how T-PSS and
Ushercell affect the growth of G. vaginalis and anaerobes com-
monly associated with BV.
Procurement of compounds. High-molecular-weight sodium
cellulose sulfate (Ushercell) was synthesized at Dextran Prod-
ucts, Ltd. (Scarborough, Ontario, Canada) according to the
method described by Usher et al. (23). Polystyrene sulfonate
(T-PSS) was synthesized by the Program for the Topical Pre-
vention of Conception and Disease (TOPCAD; Chicago, Ill.)
by free-radical polymerization of sodium styrene sulfonate in
water (C. J. Chany, R. A. Anderson, D. P. Waller, and L. J. D.
Zaneveld, unpublished data). Both were synthesized under
good manufacturing practice conditions. Ushercell and T-PSS
have peak molecular masses of 2,300 and 864 kDa, respec-
tively, and average molecular masses of 1,900 and 751 kDa,
respectively.
Bacterial strains. A total of 33 clinical isolates and two
American Type Culture Collection (ATCC) strains were used
for this study, including six genera of bacteria commonly asso-
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ciated with BV: Gardnerella, Bacteroides, Peptostreptococcus,
Prevotella, Fusobacterium, and Eubacterium. The isolates were
obtained from the Alden Research Laboratory collection,
UCLA Medical Center, Santa Monica, Calif., and from the
Obstetrics and Gynecology Research Laboratory collection,
Rush Medical Center, Chicago, Ill. All the isolates came from
patients with BV and/or pelvic infections, such as endometritis.
The isolates were stored at 70°C in skim milk (Difco Labo-
ratories, Detroit, Mich.) and subcultured two or three times in
brucella broth or in human blood bilayer Tween (HBT) agar
before testing.
G. vaginalis agar diffusion bioassay. Since G. vaginalis is
consistently associated with BV, the effect of T-PSS and Usher-
cell on G. vaginalis growth was studied first. An agar diffusion
bioassay was performed with four clinical isolates as indicator
strains. HBT agar (BD-Microbiology Systems, Cockeysville,
Md.) was chosen as a selective medium for G. vaginalis. The
polymers have a considerably larger molecular size than most
antibiotics; therefore, their diffusion through media was ex-
pected to be slower. In an effort to overcome this difficulty, the
compounds were initially tested in wells punched in the agar
plates as described below. A suspension containing approxi-
mately 107 CFU of G. vaginalis/ml was prepared and used to
inoculate two HBT agar plates. After drying for 30 min, four
wells were punched in each HBT top layer agar with a number
8 cork borer. Different concentrations of each compound in
phosphate-buffered saline (PBS) were prepared (10, 5, 2.5, 1,
0.5, 0.25 and 0.125 mg/ml) and aliquoted (200 l) into the wells
of two sets of HBT agar plates. The last well was filled with 200
l of PBS as the negative control. After a 2-h period of pred-
iffusion, the plates were incubated overnight under a 5% CO2
atmosphere at 37°C. Comparative studies were performed with
ampicillin (8 g/ml) as a positive control in a separate plate.
The sizes of the zones of inhibition surrounding the well (dis-
tance from the edge of the well to the bacteria growth) were
measured in millimeters with a vernier caliper.
Evaluation of antibacterial activity by broth dilution
method. The macrodilution broth method was performed ac-
cording to a method described by the National Committee for
Clinical Laboratory Standards (NCCLS) (15). T-PSS and
Ushercell were serially diluted in brucella broth (Difco Labo-
ratories) supplemented with sheep blood, vitamin K, and he-
min, as described in NCCLS M11-A5 (15). The medium did
not contain NaHCO3 and was reduced in an anaerobic cham-
ber in an atmosphere containing 5% CO2 for approximately
2 h prior to inoculation. The highest concentration tested was
10 mg/ml (10, 5, 2.5, 1.25, 0.625, and 0.313 mg/ml). Aliquots (1
ml) of the diluted compounds were added to 12- by 75-mm
plastic tubes. The inoculum was prepared by suspending each
bacterial strain to a turbidity equal to the 0.5 McFarland stan-
dard in unsupplemented brucella broth and diluted 1:50 in
supplemented brucella broth. Then, 1-ml aliquots of each test
strain were dispensed into the tubes that contained the diluted
compounds. The final concentration was 1  106 to 5  106
CFU/ml. The mixtures were incubated at 37°C under anaero-
bic conditions. After a 48-h incubation, the tubes were exam-
ined for growth. Comparative studies were performed with
metronidazole as the control drug. Tubes without either mi-
croorganism or drug were also tested simultaneously as nega-
tive and positive controls, respectively. The MIC was defined
as the lowest concentration of each compound that completely
inhibited growth of the tested bacteria.
Results and discussion. Both T-PSS and Ushercell inhibited
the four G. vaginalis clinical isolates in the agar diffusion bio-
assay. G. vaginalis was inhibited by T-PSS in a concentration-
dependent manner (Table 1). The growth-inhibition effect
against the four indicator strains began at 0.25 to 0.5 mg of
T-PSS/ml, depending on the strain. At the highest concentra-
tion tested (10 mg/ml), the inhibitory effect was similar to that
of ampicillin (8 g/ml).
Ushercell also had a dose-dependent growth-inhibition ef-
fect on G. vaginalis clinical isolates. Inhibition started at 0.5
mg/ml for three isolates. One of the isolates (Gv743) demon-
strated decreased susceptibility to the inhibitory activity of
Ushercell, with growth inhibition starting at 5 mg/ml (Table 1).
Table 2 depicts the MIC endpoints obtained with the broth
dilution method. Both T-PSS and Ushercell inhibited the
growth of most test isolates. In general, T-PSS was effective at
lower concentrations than Ushercell. The compounds inhib-
ited both strains of G. vaginalis and both strains of Eubacterium
lentum. All eight strains of Peptostreptococcus were inhibited by
Ushercell, and six were inhibited by T-PSS. The two strains of
Prevotella melaninogenica were not inhibited by Ushercell, and
only one strain was inhibited by T-PSS. However, both com-
pounds inhibited all strains of the other Prevotella species (P.
intermedia, P. bivia, and P. disiens). One of the three tested
strains of Bacteroides thetaiotaomicron was inhibited. None of
the Bacteroides fragilis strains was inhibited by T-PSS, and only
one strain was inhibited by Ushercell. Under the same condi-
tions, metronidazole was much more effective against all of
these microbes than either T-PSS or Ushercell, at least on a
weight/volume basis.
T-PSS and Ushercell are under clinical evaluation as active
TABLE 1. Zones of G. vaginalis growth inhibition by polystyrene





Gv284 Gv422 Gv712 Gv743
T-PSS 10 mg/ml 4 5 6 6
5 mg/ml 4 5 5 5
2.5 mg/ml 3 3 4 3
1 mg/ml 2 2 1 2
0.5 mg/ml 2 2 1 1
0.25 mg/ml 0 1 0 0
0.125 mg/ml 0 0 0 0
Ushercell 10 mg/ml 2 5 3 1
5 mg/ml 2 4 2 1
2.5 mg/ml 1 3 2 0
1 mg/ml 1 2 1 0
0.5 mg/ml 1 1 1 0
0.25 mg/ml 0 0 0 0
0.125 mg/ml 0 0 0 0
Ampicillin 8 g/ml 7 8 8 7
PBS 0 0 0 0
a Each measurement is the average inhibition distance from the edge of the
well to the edge of growth.
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ingredients for vaginal microbicide products (e.g., see refer-
ence 14). These compounds are not cytotoxic to spermatozoa
or the host cells used in the herpes and HIV assays and do not
inactivate Lactobacillus gasseri (1, 2, 26; Zaneveld et al., Pro-
gram Abstr. Microbicides 2000 Conf.). The present study dem-
onstrates that T-PSS and Ushercell also inhibit the growth of
many bacteria commonly associated with BV, eliminating the
concern that they may enhance the incidence of this disease.
Both compounds are effective against most or all tested iso-
lates of G. vaginalis, Peptostreptococcus, Prevotella, Eubacte-
rium, and Fusobacterium at concentrations of 10 mg/ml. Less
or no inhibition was found with respect to Bacteroides isolates,
particularly to B. fragilis strains. Although previous studies
have shown that sulfated or sulfonated polymers inhibit the in
vitro growth of STI-causing bacteria and the infectivity of en-
veloped viruses, including HIV (1, 2, 3, 4, 7, 9, 10, 26), this is
the first report on the inhibition of BV-associated anaerobic
bacteria by such compounds.
The recommended treatment for BV is metronidazole,
orally or intravaginally (5). However, this drug is not always
highly effective, particularly when cure rates after 1 month or
more are considered (11). Compared to the MIC levels of
metronidazole, T-PSS and Ushercell were much less effective
on a weight/volume basis against the anaerobic microbes tested
in the present study. However, the high molecular weights and
charge densities of T-PSS and Ushercell make vaginal absorp-
tion extremely unlikely, in contrast to metronidazole. In addi-
tion, Ushercell and, to a lesser extent, T-PSS have bioadhesive
properties, delaying leakage from the vagina (2, 26). Such
properties may make these compounds safer. In addition, they
may remain for longer periods of time in the vagina. It would
be worthwhile to test them as an alternative treatment for BV.
Little is known about the possible mechanism of action
whereby T-PSS and Ushercell can prevent growth of microbes.
Previous studies have shown that the mechanism of antimicro-
bial activity towards several STI-causing pathogens by these
compounds may involve receptor antagonism or mimeticism
during cell-cell fusion (1, 2, 9). This study does not address the
mechanism by which T-PSS and Ushercell exert their antimi-
crobial activity against G. vaginalis and BV-associated anaer-
obic bacteria.
The present data on the in vitro inhibitory activity of T-PSS
and Ushercell against G. vaginalis and other BV-associated
anaerobic bacteria provide additional information regarding
their safety as vaginal microbicides. The compounds have a
direct inhibitory effect on HIV and other STI-causing patho-
gens. We hypothesize that a secondary mechanism of anti-STI
action may be through a reduction in the occurrence of BV, a
condition that can increase acquisition and transmission of
TABLE 2. Inhibition of BV-associated anaerobes by polystyrene sulfonate (T-PSS) and cellulose sulfate (Ushercell) in broth dilution assay
Isolatea Bacteria species
MIC endpointsb
T-PSS (mg/ml) Ushercell (mg/ml) Metronidazole (g/ml)
10481 Fusobacterium nucleatum 1.25 5 1
11518 Fusobacterium nucleatum 1.25 10 0.25
11423 Fusobacterium gonidiaformans NEc 5 0.125
11653 Fusobacterium gonidiaformans NE 5 0.25
9052 Prevotella melaninogenica 1.25 NE 0.25
5657 Prevotella melaninogenica NE NE 0.125
11142 Prevotella intermedia 1.25 10 0.5
11168 Prevotella intermedia 1.25 10 0.25
11697 Prevotella bivia 2.5 5 2
11683 Prevotella bivia 1.25 5 0.5
653 Prevotella bivia 2.5 10 2
11579 Prevotella disiens 1.25 10 0.25
11698 Prevotella disiens 0.6 10 0.125
12066 Gardnerella vaginalis 1.25 5 1
12262 Gardnerella vaginalis 1.25 5 0.5
11658 Peptostreptococcus magnus 10 5 0.06
11598 Peptostreptococcus magnus NE 5 0.25
11287 Peptostreptococcus tetradius 1.25 5 0.06
11253 Peptostreptococcus tetradius NE 5 0.5
443 Peptostreptococcus anaerobicus 5 10 0.06
11587 Peptostreptococcus asaccharolyticus 2.5 10 0.06
11607 Peptostreptococcus asaccharolyticus 5 10 0.125
4C Peptostreptococcus asaccharolyticus 10 5 0.125
9420 Eubacterium lentum 5 5 0.5
11700 Eubacterium lentum 1.25 10 1
ATCC Bacteroides thetaiotaomicron 5 10 2
11604 Bacteroides thetaiotaomicron NE NE 0.25
11651 Bacteroides thetaiotaomicron NE NE 0.5
ATCC Bacteroides fragilis NE 10 0.5
11647 Bacteroides fragilis NE NE 0.25
11652 Bacteroides fragilis NE NE 0.5
a The numbers represent clinical isolates. B. fragilis ATCC 25285 and B. thetaiotaomicron ATCC 29741 are the NCCLS-recommended reference strains for anaerobic
antimicrobial susceptibility testing.
b Lowest concentration that completely inhibited the bacteria growth.
c NE  no effect by 10 mg/ml (the highest concentration tested).
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HIV and other STIs. Clinical studies are required to prove this
hypothesis.
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